We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-11.36%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$212M
AUM Growth
-$128M
Cap. Flow
-$78.2M
Cap. Flow %
-36.84%
Top 10 Hldgs %
61.58%
Holding
34
New
4
Increased
5
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$10.1M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$9.34M
3
UPB
Upstream Bio Inc
UPB
+$6.7M
4
KALV
KalVista Pharmaceuticals
KALV
+$5.05M
5
MREO
Mereo BioPharma
MREO
+$4.52M

Top Sells

Rank Stock Value
1
NGNE icon
Neurogene
NGNE
+$20.9M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$11.9M
3
PLRX icon
Pliant Therapeutics
PLRX
+$11.7M
4
ACLX
Arcellx
ACLX
+$8.35M
5
ORKA
Oruka Therapeutics
ORKA
+$6.97M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
26
UroGen Pharma
URGN
$1.86B
$2M 0.94%
187,843
-570,943
-75% -$6.84M
ACLX
27
DELISTED
Arcellx
ACLX
– –
-100,000
Closed -$8.35M
ACLX
28
PUT
DELISTED
Arcellx
ACLX
– –
-100,000
Closed -$8.35M
OLMA icon
29
Olema Pharmaceuticals
OLMA
$1B
– –
-1,000,000
Closed -$11.9M
OTLK icon
30
Outlook Therapeutics
OTLK
$183M
– –
-1,293,028
Closed -$6.9M
RNAC icon
31
Cartesian Therapeutics
RNAC
$229M
– –
-200,000
Closed -$3.22M
TCRX icon
32
TScan Therapeutics
TCRX
$48.6M
– –
-1,016,375
Closed -$5.06M
VTGN icon
33
VistaGen Therapeutics
VTGN
$9.89M
– –
-674,075
Closed -$2.03M
CLYM
34
Climb Bio
CLYM
$681M
– –
-248,168
Closed -$1.26M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Great Point Partners held 34 positions worth $212M, down 38% from $340M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Great Point Partners withdrew a net $78.2M in Q4 2024, closing 8 positions and reducing 13 holdings. Its most notable exit was Olema Pharmaceuticals, an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Xenon Pharmaceuticals worth $9.61M.

  • Great Point Partners's largest Q4 2024 buy was Xenon Pharmaceuticals: 245,272 shares worth $9.61M.
  • Great Point Partners added most to Ionis Pharmaceuticals in Q4 2024, an estimated $9.34M increase.
  • Great Point Partners's biggest Q4 2024 reduction was Neurogene, cutting an estimated $20.9M.
  • Great Point Partners fully exited Olema Pharmaceuticals in Q4 2024, selling an estimated $11.9M.
  • Great Point Partners's ten largest holdings make up 62% of its $212M portfolio in Q4 2024.
  • Great Point Partners opened 4 new positions and closed 8 in Q4 2024.
  • Great Point Partners's portfolio value fell 38% quarter-over-quarter to $212M.

Based on Great Point Partners's 13F filing for Q4 2024, filed 14 Feb 2025.